MTI-31
Product Specifications
Product Name Alternative
LXI-15029
UNSPSC Description
MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (Kd: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer[1].
Target Antigen
mTOR
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/mti-31.html
Purity
99.98
Solubility
DMSO : 8.33 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
C[C@@H]1N(CCOC1)C2=NC3=C(C=CC(C4=CC(C(NC)=O)=CC=C4)=N3)C(N5C6CCC5COC6)=N2
Molecular Weight
474.55
References & Citations
[1]Zhang Q, et, al. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer. Clin Cancer Res. 2019 Jun 15;25(12):3630-3642. |[2]Qian J, et, al. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer. Oncotarget. 2016 Oct 11;7(41):67071-67086. |[3]Wang X, et, al. Non-immunogenic, low-toxicity and effective glioma targeting MTI-31 liposomes . J Control Release. 2019 Dec 28;316:381-392.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-126077/MTI-31-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-126077/MTI-31-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
1567915-38-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
